摘要
目的:探讨吉非替尼对肺癌患者血清血管内皮生长因子(VEGF)、细胞角蛋白(CYFRA21-1)、糖类抗原(CA125)、癌胚抗原(CEA)及基质金属蛋白酶(MMP-9)水平影响研究及临床疗效。方法:选取前来我院就诊的已确诊的晚期非小细胞肺癌患者68例,随机分为对照组和治疗组,每组34例。对照组给予多西紫杉醇治疗,治疗组采用吉非替尼治疗,比较治疗前后两组患者血清VEGF、CYFRA21-1、CA125、CEA及MMP-9水平的变化、临床疗效及3年生存率。结果:治疗组总有效率及3年后生存率均明显高于对照组(P<0.05);治疗后,两组患者血清VEGF、CYFRA21-1、CA125、CEA及MMP-9水平均较治疗前显著降低(P<0.05),治疗组患者血清VEGF、CYFRA21-1、CA125、CEA及MMP-9水平低于对照组(P<0.05)。结论:吉非替尼对晚期非小细胞肺癌患者的治疗效果良好,其机制可能与降低血清VEGF、CYFRA21-1及CA125、CEA、MMP-9水平有关。
Objective： To investigate the effects of gefitinib on the serum CA125, CEA and MMP-9 levels and clinical efficacy of patients with lung cancer. Methods： A total of 68 patients with advanced non-small cell lung cancer were collected from our hospital and randomly divided into the control group and experimental group with 34 cases in each group. Patients in the control group were treated by docetaxel injection, while patients in the experiment group were treated by gefitinib. After treatment, the serum VEGF, CYFRA21-1, CA125, CEA and MMP - 9 levels, clinical efficacy and 3 years survival rateof the two groups were compared before and after treatment. Results： The total effective rate and 3-year survival rate of the experimental group were significant higher than those of the control group （P〈0.05）. After treatment, the serum VEGF, CYFRA21-1, CA125, CEA and MMP - 9 levels of both groups were decreased （P〈0.05）; the serum VEGF, CYFRA21-1, CA125, CEA and MMP - 9 levels of experimental group were lower than those of the control group （P〈0. 05）. Conclusion： Gefitinib could effectively treat advanced non-small cell lung cancer, which might be related to reduce the serum VEGF, CYFRA21-1, CA125, CEA and MMP-9 levels.
出处
《现代生物医学进展》
CAS
2016年第34期6754-6757,共4页
Progress in Modern Biomedicine
基金
陕西省科技厅自然科学基金项目(2007C2612)
